Skip to main content
main-content

Oncology

Immune checkpoint inhibitors viable in advanced cancer complicated by HIV

Virus cells_3D

Immune checkpoint inhibitor therapy is well tolerated by patients with HIV infection and advanced-stage cancer and does not appear to adversely affect HIV viral load or CD4 cell count, suggest results of a systematic data review.

Lung cancer OS benefit with patient-reported symptom monitoring

Older man using tablet

A web-based patient-reported system for monitoring symptoms after treatment for lung cancer is associated with significantly better overall survival than standard scheduled imaging, trial results show.

Hepatitis screening “may be warranted” following cancer diagnosis

Blood sample

The prevalence of hepatitis B virus and hepatitis C virus infection in patients with newly diagnosed cancer is similar to that of the US population, but a “substantial proportion” of patients are unaware of their infection, research shows.

SABCS 2018: PD-L1 in immune cells predicts atezolizumab plus nab-paclitaxel efficacy in metastatic triple-negative breast cancer

Presenting author Leisha Emens outlines exploratory efficacy analysis results from IMpassion130 showing that programmed cell death ligand 1 in immune cells is a robust predictive biomarker for selecting women with metastatic triple-negative breast cancer who may benefit from first-line atezolizumab plus nab-paclitaxel treatment (6:19).

SABCS 2018: Circulating tumour cell count could aid first-line hormone versus chemotherapy treatment decisions

Francois-Clement Bidard reports findings that circulating tumour cell count could help oncologists choose between first line hormone therapy and chemotherapy in women with oestrogen receptor positive, HER2-negative metastatic breast cancer (3:23).

SABCS 2018: Achieving pCR after neoadjuvant chemotherapy improves event-free and overall survival

Aditya Bardia explains the importance of research done by him and his colleagues validating pCR as a robust surrogate biomarker for outcomes particularly in women with triple negative and HER2-positive breast cancer (5:26).  

SABCS 2018: Impact of breast cancer surgery on quality of life

Ann Partridge discusses the E5103 study findings regarding the quality of life issues faced by women undergoing mastectomy and the need to continue monitoring them long term (5:14).

SABCS 2018: Delayed initiation of adjuvant chemotherapy significantly impacts survival in women with triple-negative breast cancer

Presenting author Zaida Morante discusses findings showing that the greater the delay in initiating adjuvant chemotherapy the worse a woman’s outcome in terms of overall and disease-free survival (2:59).

SABCS 2018: Low-dose tamoxifen prevents breast intraepithelial neoplasia recurrence

Andrea DeCensi outlines his study findings demonstrating that low-dose tamoxifen 5 mg/day significantly lowers the recurrence of intraepithelial neoplasia versus placebo without increasing endometrial cancer and deep vein thrombosis (3:32).

SABCS 2018: Radiotherapy comparable to axillary lymph node dissection for locoregional control in breast cancer patients with a positive sentinel lymph node

Emiel Rutgers gives an overview of the 10-year follow-up results from the EORTC AMAROS trial demonstrating that radiotherapy has equivalent locoregional control to that of axillary lymph node dissection  but with a reduced risk of lymphedema (4:28).

SABCS 2018: Adjuvant trastuzumab emtansine improves invasive disease-free survival versus trastuzumab after neoadjuvant chemotherapy in HER2-positive women

Charles Geyer reports his phase III study findings showing the potential for adjuvant trastuzumab emtansine as a new standard of care in women with HER-2 positive, early breast cancer and residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy (7:56).

SABCS 2018: Accelerated partial versus whole breast irradiation for controlling ipsilateral breast tumour recurrence

Frank Vicini discusses his research showing that while partial breast irradiation after lumpectomy is not equivalent to whole breast irradiation for long-term control of ipsilateral breast tumour recurrence, the difference is small (2:27).

15-02-2019 | Prostate cancer | News | Article

Further support for [177Lu]-PSMA-617 in men with mCRPC

Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.

15-02-2019 | Prostate cancer | News | Article

Real-world data confirm better mCRPC OS with hormonal therapy in Black versus White men

An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.

14-02-2019 | Prostate cancer | News | Article

Long-term data support SBRT for low-, intermediate-risk prostate cancer

Stereotactic body radiotherapy has a favorable long-term disease control and safety profile in the setting of low- or intermediate-risk prostate cancer, say US researchers who analyzed individual patient data from over 2000 prospectively treated men.

12-02-2019 | Prostate cancer | News | Article

Conservative management of low-risk prostate cancer increasing in USA

US patients with low-risk localized prostate cancer are increasingly being managed with active surveillance or watchful waiting, finds a database analysis.

Docetaxel Use With ADT Challenged For High-Risk, Nonmetastatic Prostate Cancer

Combining androgen-deprivation therapy with docetaxel failed to improve PSA–progression-free survival in men with high-risk prostate cancer and a rising PSA level after local therapy Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits